Day 1 – Tuesday, 16 Sept 2025Tuesday, September 16, 2025 - ET (Eastern Time, GMT-05:00)

Following a slow period for both M&A and IPO markets between 2022 and the first half of 2024 there has been a welcome uptick across both markets, bringing optimism and expectation to startups and investors alike. Our panel of medtech leaders and investors discuss the key factors in the return of medtech exits, what it means moving forward and strategies for companies effectively approaching exits.

• A review of the IPO and M&A markets over the past 12 months
• Expectations and trends for the next 18 months
• When and how companies should approach exit strategies

Amid a growing M&A market and better macroeconomic conditions, major strategics are deploying more capital and entering into more partnerships with smaller companies to drive growth. Hear from our mix of strategic business development and CVC executives to discuss best practice for engaging with these strategics as well as hearing their priorities and areas of focus over the next 12-18 months.

• The best time to approach strategics, and strategies for getting in front of decision makers
• Milestones strategic partners look for when considering partnership
• The areas major strategics are prioritising in the next 18 months

While the excitement and anticipation is huge, what is the actual way forward with AI? How are pharma companies using and leveraging AI to deliver commercial and patient benefits?

• How is pharma moving from AI hype to practical implementation?
• Highlighting examples of how pharma companies are currently leveraging AI to improve patient care and treatment efficacy
• Exploring how AI is being utilized to enhance commercial strategies, streamline processes, and drive revenue growth
• Discussing the critical factors pharma companies must address to ensure effective and sustainable AI adoption

Step into the future of pharma innovation. This open format discussion with industry leaders will illuminate the groundbreaking technologies poised to revolutionize the industry. But there’s a catch, we won’t be talking about AI! From the power of digital tech in drug discovery to the transformative potential of personalized medicine, we'll explore how emerging digital technologies are reshaping patient care, clinical trials, and the entire pharma landscape. Discover the cutting-edge advancements that will define the next era of pharmaceutical excellence.

Women’s health has long been underserved in healthcare, in recent years the tide has turned with greater investment flowing into the sector. Now the companies at the forefront of women’s health are engaged in Series C and later funding rounds to truly scale and commercialize their technology. Our panel of women’s health executives discuss their experience and the investment landscape at greater scales.

• Challenges and trends within the women’s health space
• Women’s health investment landscape
• Market opportunities in women’s health

In an industry worth over $500B, and with near constant innovation, it is easy to lose sight of the macro trends within the sector. With general optimism returning to the space, some therapeutic areas could be poised for significant growth powered by an influx of funding. Hear from our panel of CEOs and medtech leaders on their priorities and challenges from operating in the hottest areas within the industry.

• Reviewing the “hottest” areas in medtech
• Focus areas for strategic investors and tier 1 BD teams
• The benefits and challenges of being an innovator in a competitive area

Get the inside scoop on how pharma giants are leveraging strategic acquisitions and integrations to fuel unprecedented growth. We'll dissect the latest trends, reveal the critical factors for evaluating potential partners, and provide actionable strategies for navigating the complex world of pharma business development.

• Overview of the current landscape of pharma digital tech acquisitions and integrations – where is Pharma’s appetite?
• Assessing potential partners, ensuring strategic alignment and maximizing ROI
• Strategies for overcoming the hurdles of integrating acquired technologies – Are we there yet?
• Leveraging tech acquisitions for accelerated growth and competitive advantage in the pharma industry

Dive into the dynamic world of pharma tech investment. This panel brings together leading corporate VC’s to dissect the latest trends, analyze ROI potential, and explore the unique opportunities and challenges of funding groundbreaking pharmaceutical technologies. Discover how smart money is fuelling the future of medicine and learn the strategies for navigating this rapidly evolving and high-stakes landscape.

• Exploring the investment trends in the pharma tech space – what is the ROI?
• Discussing the role of corporate venture capital in funding pharma tech innovation
• Analysing the opportunities and challenges for investors in the rapidly evolving pharma tech landscape

As the boundaries between medtech and digital health blur, AI and Software as a Medical Device (SaMD) are at the forefront of the techmed revolution. But innovation alone isn’t enough, success in this space depends on verifiable quality training data sources, regulatory adaptation, and investor confidence. This panel brings together techmed innovators, regulatory experts, and investors to explore how AI and SaMD are reshaping healthcare and where the biggest opportunities lie.

• Investor perspectives, how trust, ethics and cybersecurity impact investment in AI, SaMD and techmed
• Characteristics and importance of a good AI training dataset
• The role of the FDA in keeping up with and ensuring safety of new technologies

Regulatory approval continues to be an essential milestone in the commercialization of medtech products, it constitutes a big step in the de-risking of a medtech investment and proves the safety of medical technologies. Our panel discusses the importance of efficient and effective strategies in streamlining and maximising the opportunity the FDA presents.

• How reform under the Trump administration may alter the FDA workflow
• The importance of looking ahead to reimbursement opportunities in approval strategy
• Common pitfalls and challenges faced in the approval process

The convergence of technology and biology is ushering in a new era of pharmaceutical innovation. This panel explores the dynamic partnership between TechBio startups and established pharma companies, examining how their combined expertise is revolutionizing drug discovery, development, and delivery. Discover the groundbreaking approaches that are shaping the next generation of therapeutics.

• Examining how AI, machine learning, and computational biology are accelerating target identification, drug design, and clinical trial optimization
• Exploring successful partnership and collaborative models for TechBio & Pharma
• Analysing the challenges and opportunities in translating cutting-edge discoveries into accessible and effective patient treatments
• Looking to the future – how can we use digital tech across the whole drug value chain?

Regulatory changes, especially those focused on emerging technologies, are increasingly impacting business models and compliance. This panel brings together experts to explore how companies can navigate this complex landscape. We'll delve into flexible approaches to policy development, such as regulatory sandboxes, outcome-based regulation, and adaptive regulation, and discuss strategies for managing the challenges of regulatory uncertainty and ensuring continued innovation.

• Strategies for managing the reduced speed of technology adoption, potential loss of investments, and increased compliance costs due to complex regulations
• Exploring how companies use technology to make sure they're following the rules, especially with data privacy
• How to proactively adapt to regulatory changes to avoid competitive disadvantages and capitalize on new opportunities

Despite the current tough fundraising landscape, venture capital remains the dominant source of investment in medtech and digital health. However, shifting dynamics are leading these companies to ask, “are VCs the only option for fundraising?” Our panel of investors and CEOs discuss emerging sources of funding from private equity and venture debt to government initiatives and strategic partnerships.

• Changes in funding models in recent years
• Expectations and milestones different sources of funding hold for their investments
• How companies in different stages of development can benefit from different funding sources

Funding is critical for medtech and digital health growth and commercialization, it is therefore essential for such companies to have a good understanding of investor expectations and a clear fundraising strategy when approaching investment opportunities. Our panel of investors discuss key milestones and qualities they look for from potential investments, and strategies for effectively communicating value in investor meetings.

• Priorities for investors in different stages of development
• How to build an effective investment strategy
• Strategies for successful investor communication

Imagine a future where clinical trials are seamlessly integrated into patients' lives, powered by intelligent technologies designed with human needs at their core. This session explores that future. We'll delve into the landscape of AI-powered, yet human-centred trials, examining how we rigorously validate these technologies before deployment. Join us as we explore AI's impact across all trial stages, address the critical need for unbiased algorithms, and discuss how AI can democratize access to trials for underserved communities. Discover how technology is reshaping clinical research to be more accessible, efficient, and patient-friendly

• What does the future of AI-powered but human centred clinical trials look like?
• How do we validate technologies before they get introduced into clinical trials?
• Exploring the use of AI in the various clinical trial stages
• How can we ensure that algorithms are unbiased and fair?
• Can AI help to improve access to clinical trials for underserved populations?

Precision medicine holds the promise of tailored treatments, driven by the power of AI and data. This panel explores the immense opportunities and significant challenges in realizing this vision. We'll delve into how AI and data analytics are transforming healthcare, while also addressing the critical barriers to widespread adoption and discussing strategies to overcome them.

• How can we effectively combine diverse data sources (genomic, clinical, lifestyle) to create comprehensive patient profiles for AI-driven precision medicine?
• What are the risks of bias in AI algorithms, and how can we ensure fairness, transparency, and patient trust in personalized medicine?
• Exploring how we bridge the gap between AI-generated insights and clinical implementation, ensuring that personalized treatments are accessible and effective for all patients?